---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-058140"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-05-18T12:15:16+00:00"
generated_at: "2026-05-18T12:21:49.339373+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead

## Summary
- Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.
- GX-03 is a topical therapy in Phase 2 trial for moderate-to-severe atopic dermatitis (eczema).
- Hahn cited personal family experience with atopic dermatitis as motivation for his role.
- CEO Bradley Burnam highlighted Hahn's scientific rigor, regulatory expertise, and patient focus.

## SEC filing metadata
- accession: 0001213900-26-058140
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-05-18T12:15:16+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026058140/0001213900-26-058140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026058140/ea0291223-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-058140
- JSON: https://secwatch.observer/filing/0001213900-26-058140.json
- Plain text: https://secwatch.observer/filing/0001213900-26-058140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.